{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:00:41Z","timestamp":1788742841653,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172520"],"award-info":[{"award-number":["81172520"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202087"],"award-info":[{"award-number":["81202087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202088"],"award-info":[{"award-number":["81202088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472462"],"award-info":[{"award-number":["81472462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Shanghai Municipal Science and Technology Commission","award":["12ZR1446400"],"award-info":[{"award-number":["12ZR1446400"]}]},{"name":"Technology Innovation Act Plan of the Shanghai Municipal Science and Technology Commission","award":["14411950200"],"award-info":[{"award-number":["14411950200"]}]},{"name":"Technology Innovation Act Plan of the Shanghai Municipal Science and Technology Commission","award":["14411950201"],"award-info":[{"award-number":["14411950201"]}]},{"name":"Joint Research Project of Emerging Cutting-edge Technology of the Shanghai Shen-kang Hospital Development Center","award":["SHDC12014103"],"award-info":[{"award-number":["SHDC12014103"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.biocel.2015.11.014","type":"journal-article","created":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T19:35:06Z","timestamp":1448739306000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"Junjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bockhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biocel.2015.11.014_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0099-5428(05)32002-8","article-title":"Niclosamide: comprehensive profile","volume":"32","author":"Al-Hadiya","year":"2005","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"Andrews","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biocel.2015.11.014_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0020","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ijc.28782","article-title":"MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer","volume":"135","author":"Bai","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biocel.2015.11.014_bib0025","doi-asserted-by":"crossref","first-page":"e7124","DOI":"10.1371\/journal.pone.0007124","article-title":"Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling","volume":"4","author":"Balgi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2015.11.014_bib0030","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0035","doi-asserted-by":"crossref","unstructured":"Baselga, J., Verma, S., Ro, J., Guardino, E., Fang, L,. et al., 2013. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. AACR Annual Meeting, Abstract LB-63.","DOI":"10.1158\/1538-7445.AM2013-LB-63"},{"key":"10.1016\/j.biocel.2015.11.014_bib0040","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(12)60971-4","article-title":"Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer","volume":"379","author":"Brede-Hekimian","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.biocel.2015.11.014_bib0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/1541-7786.MCR-13-0212","article-title":"Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer","volume":"11","author":"Chen","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0050","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/bcr3575","article-title":"Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors","volume":"15","author":"Chen","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/0008-5472.CAN-13-2420","article-title":"HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2","volume":"74","author":"Cheng","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0060","doi-asserted-by":"crossref","first-page":"e1336","DOI":"10.1038\/cddis.2014.285","article-title":"Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment","volume":"5","author":"Ciavardelli","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biocel.2015.11.014_bib0065","doi-asserted-by":"crossref","first-page":"29753","DOI":"10.18632\/oncotarget.4995","article-title":"The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells","volume":"6","author":"Cieslar-Pobuda","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biocel.2015.11.014_bib0070","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4161\/cc.26899","article-title":"Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib","volume":"13","author":"De Luca","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biocel.2015.11.014_bib0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2013.01.022","article-title":"Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer","volume":"23","author":"Dong","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biocel.2015.11.014_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","article-title":"Molecular predictors of response to trastuzumab and lapatinib in breast cancer","volume":"7","author":"Esteva","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0090","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/carcin\/bgu045","article-title":"Cell adhesion molecules and their relation to (cancer) cell stemness","volume":"35","author":"Farahani","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biocel.2015.11.014_bib0095","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr3650","article-title":"Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models","volume":"16","author":"Formisano","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0100","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1038\/sj.onc.1209598","article-title":"Mitochondria as therapeutic targets for cancer chemotherapy","volume":"25","author":"Galluzzi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2015.11.014_bib0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2015.11.014_bib0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopha.2010.10.004","article-title":"Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern","volume":"65","author":"Iseri","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biocel.2015.11.014_bib0115","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.18632\/oncotarget.3548","article-title":"Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death","volume":"6","author":"Jangamreddy","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biocel.2015.11.014_bib0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-012-2252-9","article-title":"PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells","volume":"136","author":"Jegg","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biocel.2015.11.014_bib0125","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","article-title":"Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0130","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1470-2045(13)70463-7","article-title":"Dual HER2 targeting for early breast cancer","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0140","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.18632\/oncotarget.2806","article-title":"Hypoxia\/HIF1alpha induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2","volume":"6","author":"Karakashev","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biocel.2015.11.014_bib0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","article-title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+cohort in EGF103009, a phase II study","volume":"10","author":"Kaufman","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0150","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/bcj.2011.38","article-title":"Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production","volume":"1","author":"Khanim","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biocel.2015.11.014_bib0155","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/onc.2013.285","article-title":"Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer","volume":"33","author":"Kim","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2015.11.014_bib0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canlet.2015.04.025","article-title":"Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines","volume":"364","author":"Kondaveeti","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biocel.2015.11.014_bib0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biocel.2015.11.014_bib0170","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-13-0095","article-title":"Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer","volume":"12","author":"Li","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biocel.2015.11.014_bib0175","doi-asserted-by":"crossref","first-page":"e74670","DOI":"10.1371\/journal.pone.0074670","article-title":"Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2015.11.014_bib0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","article-title":"Multi-targeted therapy of cancer by niclosamide: a new application for an old drug","volume":"349","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biocel.2015.11.014_bib0185","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0190","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0195","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0200","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/bcr3675","article-title":"Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells","volume":"16","author":"Lombardo","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1535-7163.MCT-13-0555","article-title":"Effect of niclosamide on basal-like breast cancers","volume":"13","author":"Londono-Joshi","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biocel.2015.11.014_bib0210","doi-asserted-by":"crossref","first-page":"e29290","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/beta-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2015.11.014_bib0215","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0220","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/onc.2009.410","article-title":"Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha","volume":"29","author":"Merkhofer","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2015.11.014_bib0225","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","article-title":"Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations","volume":"71","author":"Osada","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0230","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5483\/BMBRep.2011.44.8.517","article-title":"Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death","volume":"44","author":"Park","year":"2011","journal-title":"BMB Rep."},{"key":"10.1016\/j.biocel.2015.11.014_bib0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2014.06.012","article-title":"Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy","volume":"352","author":"Pavese","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biocel.2015.11.014_bib0240","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1158\/0008-5472.CAN-09-0834","article-title":"Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high\/CD24low\/HER2low breast cancer stem cells","volume":"69","author":"Reim","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0245","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1158\/0008-5472.CAN-08-3343","article-title":"Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells","volume":"69","author":"Santisteban","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-14-1824","article-title":"High HER2 expression correlates with response to the combination of lapatinib and trastuzumab","volume":"21","author":"Scaltriti","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ccr.2013.02.021","article-title":"ROS links glucose metabolism to breast cancer stem cell and EMT phenotype","volume":"23","author":"Schieber","year":"2013","journal-title":"Cancer Cell."},{"key":"10.1016\/j.biocel.2015.11.014_bib0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2001-1326-3-17","article-title":"Clinical significance of epithelial-mesenchymal transition","volume":"3","author":"Steinestel","year":"2014","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biocel.2015.11.014_bib0265","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1200\/JCO.2007.13.5202","article-title":"dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer","volume":"26","author":"Storniolo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0270","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.18632\/oncotarget.3023","article-title":"FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells","volume":"6","author":"Taliaferro-Smith","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biocel.2015.11.014_bib0275","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/jcb.22065","article-title":"The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells","volume":"106","author":"Wang","year":"2009","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.biocel.2015.11.014_bib0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2013.06.022","article-title":"RON confers lapatinib resistance in HER2-positive breast cancer cells","volume":"340","author":"Wang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biocel.2015.11.014_bib0285","doi-asserted-by":"crossref","first-page":"e74538","DOI":"10.1371\/journal.pone.0074538","article-title":"Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2015.11.014_bib0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/B978-0-12-800097-7.00005-1","article-title":"Reprogramming and carcinogenesis--parallels and distinctions","volume":"308","author":"Wasik","year":"2014","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.biocel.2015.11.014_bib0295","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cncr.28465","article-title":"Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer","volume":"120","author":"Welslau","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.biocel.2015.11.014_bib0300","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-12-0155-T","article-title":"Expression of Wnt3 activates Wnt\/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells","volume":"10","author":"Wu","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biocel.2015.11.014_bib0305","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1073\/pnas.0602468103","article-title":"A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer","volume":"103","author":"Xia","year":"2006","journal-title":"Proc. Natl. Acad Sci. U S A"},{"key":"10.1016\/j.biocel.2015.11.014_bib0310","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1535-7163.MCT-09-1041","article-title":"Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA","volume":"9","author":"Xia","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biocel.2015.11.014_bib0315","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-3396","article-title":"Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer","volume":"20","author":"Zhang","year":"2014","journal-title":"Clin. Cancer Res."}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272515300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272515300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:01:31Z","timestamp":1761202891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272515300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":63,"alternative-id":["S1357272515300686"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2015.11.014","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2015.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}